



## Contents

### Phenotypes

**359** Further delineation of the *MECP2* duplication syndrome phenotype in 59 French male patients, with a particular focus on morphological and neurological features

*M Miguet, L Faivre, J Amiel, M Nizon, R Touraine, F Prieur, L Pasquier, M Lefebvre, J Thevenon, C Dubourg, S Julia, C Sarret, G Remerand, C Francannet, F Laffargue, O Boespflug-Tanguy, A David, B Isidor, J Vigneron, B Leheup, L Lambert, C Philippe, M Béri-Dexheimer, J-M Cuisset, J Andrieux, G Plessis, A Toutain, L Guibaud, V Cormier-Daire, M Rio, J-P Bonnefont, B Echenne, H Joutel, L Burglen, S Chantot-Bastarud, T Bienvenu, C Baumann, L Perrin, S Drumat, P-S Jouk, K Dieterich, F Devillard, D Lacombe, N Philip, S Sigaudy, A Moncla, C Missirian, C Badens, N Perretou, C Thauvin-Robinet, R AChro-Puce, J-M Pedespan, C Rooryck, C Goizet, C Vincent-Delorme, B Duban-Bedu, N Bahi-Buisson, A Afenjar, K Maincent, D Héron, J-L Alessandri, D Martin-Coignard, G Lesca, M Rossi, M Raynaud, P Callier, A-L Mosca-Boidron, N Marle, C Coutton, V Satre, C L Caignec, V Malan, S Romana, B Keren, A-C Tabet, V Kremer, S Scheidecker, A Vigouroux, M Lackmy-Port-Lis, D Sanlaville, M Till, M Carneiro, B Gilbert-Dussardier, M Willems, H Van Esch, V D Portes, S El Chehadeh*

### Position statement

**372** Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group

*A Taylor, A F Brady, I M Frayling, H Hanson, M Tischkowitz, C Turnbull, L Side, on behalf of the UK Cancer Genetics Group (UK-CCG)*

### Diagnostics

**378** High predictive value of brain MRI imaging in primary mitochondrial respiratory chain deficiency

*I de Beaurepaire, D Grévent, M Rio, I Desguerre, P de Lonlay, R Levy, V Dangouloff-Ros, J-P Bonnefont, G Barcia, B Funalot, C Besmond, M D Metodieff, B Ruzzenente, Z Assouline, A Munnich, A Rödig, N Boddart*

### Cancer genetics

**384** Tumour risks and genotype–phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes *SDHB*, *SDHC* and *SDHD*

*K A Andrews, D B Ascher, D E V Pires, D R Barnes, L Vialard, R T Casey, N Bradshaw, J Adlard, S Aylwin, P Brennan, C Brewer, T Cole, J A Cook, R Davidson, A Donaldson, A Fryer, L Greenhalgh, S V Hodgson, R Irving, F Laloo, M McConachie, V P M McConnell,*

*P J Morrison, V Munday, S-M Park, H L Simpson, K Snape, S Stewart, S E Tomkins, Y Wallis, L Izatt, D Goudie, R S Lindsay, C G Perry, E R Woodward, A C Antoniou, E R Maher*

**395** Evidence for genetic anticipation in von Hippel-Lindau syndrome

*L Aronoff, D Malkin, K van Engelen, B Gallinger, J Wasserman, R H Kim, A Villani, M S Meyn, H Druker*

### New disease loci

**403** Autosomal recessive chondrodysplasia with severe short stature caused by a biallelic *COL10A1* variant

*N ul Ain, O Makitie, S Naz*

**408** Dominant *ELOVL1* mutation causes neurological disorder with ichthyotic keratoderma, spasticity, hypomyelination and dysmorphic features

*A Kutkowska-Każmierczak, M Rydzanicz, A Chlebowski, K Kłosowska-Kosicka, A Mika, J Gruchota, E Jurkiewicz, C Kowalewski, A Pollak, T J Stradowska, T Kmiec, R Jakubowski, P Gasperowicz, A Walczak, D Śladowski, E Jankowska-Steifer, L Korniszewski, J Kosińska, E Obersztyn, W Nowak, T Ślodziński, A Dziembowski, R Płoski*

### Complex traits

**415** Genome-wide association study identifies *ERBB4* on 2q34 as a novel locus associated with sperm motility in Japanese men

*Y Sato, A Tajima, T Sato, S Nozawa, M Yoshiike, I Imoto, A Yamauchi, T Iwamoto*

### Clinical guidelines

**422** Diagnostic strategy in segmentation defect of the vertebrae: a retrospective study of 73 patients

*M Lefebvre, A Dieux-Coeslier, G Baujat, E Schaefer, S-O Judith, A Bazin, L Pinson, T Attie-Bitach, C Baumann, M Fradin, G Pierquin, S Julia, C Quélin, B Doray, S Berg, C Vincent-Delorme, L Lambert, N Bachmann, D Lacombe, B Isidor, N Laurent, R Joelle, P Blanchet, S Odent, D Kervran, N Leporrier, C Abel, K Segers, F Guiliano, E Ginglinger-Fabre, A Selicorni, A Goldenberg, S El Chehadeh, C Francannet, B Demeer, Y Duffourd, C Thauvin-Robinet, A Verloes, V Cormier-Daire, J B Riviere, L Faivre, J Thevenon*

### Miscellaneous

**429** Correction: Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study

Cover credit: Using principal component analysis to test the homogeneity of a research population sample and define outliers from Sato *Y et al*, supplementary figure S1



Adopted as the official Journal of the Canadian College of Medical Geneticists

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://authors.bmj.com/open-access/>

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics <http://publicationethics.org/>

equator network

recycle  
When you have finished with this please recycle it

The online version of this article contains multiple choice questions hosted on BMJ Learning.